Edition:
United Kingdom

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

198.86USD
22 Nov 2017
Change (% chg)

$-0.72 (-0.36%)
Prev Close
$199.58
Open
$199.70
Day's High
$199.70
Day's Low
$197.01
Volume
101,598
Avg. Vol
124,196
52-wk High
$200.00
52-wk Low
$103.55

Select another date:

Thu, Oct 26 2017

BRIEF-Abiomed Q2 earnings per share $0.54

* Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc, a maker of catheter-based heart pumps, and venture capital firm Pitango.

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc , a maker of catheter-based heart pumps, and venture capital firm Pitango.

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM, Sept 28 Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc , a maker of catheter-based heart pumps, and venture capital firm Pitango.

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​

BRIEF-ABIOMED says CFO Michael Tomsicek resigns

* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year

BRIEF-Abiomed reports Q1 EPS $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29 pct over prior year

BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery

* New study with Abiomed's Impella 2.5® heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:

Select another date: